Related Experiment Video
Updated: Jun 11, 2025

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
6.9K
Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials
Arnaud Bayle1, Laila Belcaid2, Sophie Cousin3
1DITEP, Gustave Roussy, Villejuif, France.
NPJ Precision Oncology
|October 7, 2024
Abstract:
Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study. Our analysis of two large precision medicine studies used tumor fraction from ctDNA to develop a predictive model, demonstrating notable predictive accuracy and aiding in patient selection.

